JP2012040024A5 - - Google Patents

Download PDF

Info

Publication number
JP2012040024A5
JP2012040024A5 JP2011258048A JP2011258048A JP2012040024A5 JP 2012040024 A5 JP2012040024 A5 JP 2012040024A5 JP 2011258048 A JP2011258048 A JP 2011258048A JP 2011258048 A JP2011258048 A JP 2011258048A JP 2012040024 A5 JP2012040024 A5 JP 2012040024A5
Authority
JP
Japan
Prior art keywords
composition
component
scfv
domain
tie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011258048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012040024A (ja
JP5383780B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012040024A publication Critical patent/JP2012040024A/ja
Publication of JP2012040024A5 publication Critical patent/JP2012040024A5/ja
Application granted granted Critical
Publication of JP5383780B2 publication Critical patent/JP5383780B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011258048A 2004-01-16 2011-11-25 レセプターを活性化し得る融合ポリペプチド Expired - Fee Related JP5383780B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53696804P 2004-01-16 2004-01-16
US60/536,968 2004-01-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006549631A Division JP4906094B2 (ja) 2004-01-16 2005-01-14 レセプターを活性化し得る融合ポリペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012252302A Division JP2013031462A (ja) 2004-01-16 2012-11-16 レセプターを活性化し得る融合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2012040024A JP2012040024A (ja) 2012-03-01
JP2012040024A5 true JP2012040024A5 (enExample) 2013-01-17
JP5383780B2 JP5383780B2 (ja) 2014-01-08

Family

ID=34807067

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006549631A Expired - Lifetime JP4906094B2 (ja) 2004-01-16 2005-01-14 レセプターを活性化し得る融合ポリペプチド
JP2011258048A Expired - Fee Related JP5383780B2 (ja) 2004-01-16 2011-11-25 レセプターを活性化し得る融合ポリペプチド
JP2012252302A Withdrawn JP2013031462A (ja) 2004-01-16 2012-11-16 レセプターを活性化し得る融合ポリペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006549631A Expired - Lifetime JP4906094B2 (ja) 2004-01-16 2005-01-14 レセプターを活性化し得る融合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012252302A Withdrawn JP2013031462A (ja) 2004-01-16 2012-11-16 レセプターを活性化し得る融合ポリペプチド

Country Status (10)

Country Link
US (1) US7534604B2 (enExample)
EP (1) EP1709081B1 (enExample)
JP (3) JP4906094B2 (enExample)
AT (1) ATE504599T1 (enExample)
AU (1) AU2005206536B2 (enExample)
CA (1) CA2550551C (enExample)
DE (1) DE602005027309D1 (enExample)
DK (1) DK1709081T3 (enExample)
ES (1) ES2364147T3 (enExample)
WO (1) WO2005070966A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
KR20080077238A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
JP5167155B2 (ja) * 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
MX2010009894A (es) 2008-03-14 2011-02-22 Transgene Sa Anticuerpo contra csf-1r.
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CN102307902B (zh) * 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
KR101688522B1 (ko) * 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
EP2519544A1 (en) * 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2420253A1 (en) * 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
CA2865501A1 (en) * 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN105636982B (zh) 2013-09-16 2020-06-23 健康与环境慕尼黑德国研究中心赫姆霍茨中心(有限责任公司) 用于治疗hbv感染和相关病症的结合免疫效应细胞表面抗原和hbv抗原的双或多特异性多肽
MX389442B (es) * 2013-11-11 2025-03-20 Chugai Pharmaceutical Co Ltd Región variable de anticuerpo modificada que contiene molécula de unión al antígeno.
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
WO2016076345A1 (ja) * 2014-11-11 2016-05-19 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN116333138A (zh) 2015-07-30 2023-06-27 宏观基因有限公司 Pd-1结合分子和其使用方法
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
IL258521B2 (en) 2015-10-08 2024-01-01 Macrogenics Inc Combination therapy for the treatment of cancer
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
EP4653464A2 (en) 2016-12-23 2025-11-26 MacroGenics, Inc. Adam9-binding molecules, and methods of use thereof
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス,インコーポレーテッド 二重特異性cd16結合分子、及び疾患の治療におけるその使用
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
BR112021001693A2 (pt) 2018-08-03 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno contendo dois domínios de ligação ao antígeno q ligados entre si
KR20220139886A (ko) 2020-01-08 2022-10-17 리제너론 파아마슈티컬스, 인크. 진행성 골화성 섬유이형성증의 치료
EP4106813A4 (en) 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
PH12022500013A1 (en) 2020-03-31 2023-09-11 Chugai Pharmaceutical Co Ltd Dll3-targeting multispecific antigen-binding molecules and uses thereof
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2003092611A2 (en) 2002-05-03 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels

Similar Documents

Publication Publication Date Title
JP2012040024A5 (enExample)
JP2012504943A5 (enExample)
JP2017176174A5 (enExample)
NZ600112A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
MX341921B (es) Proteinas de union a antigeno.
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2014205674A5 (enExample)
NZ602320A (en) Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
CL2013001168A1 (es) Polipeptido que comprende cuando menos dos dominios de enlace de antigeno de inmunoglobulina que se unen al receptor de quimiocina cxcr2; metodo para tratar enfermedad pulmonar obstructiva crónica (copd) o de las exacerbaciones de la copd.
JP2014503189A5 (enExample)
JP2014533239A5 (enExample)
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
JP2014509837A5 (enExample)
JP2014515602A5 (enExample)
WO2008016854A3 (en) Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
JP2014534239A5 (enExample)
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
JP2013241409A5 (enExample)
JP2013527762A5 (enExample)
JP2013527761A5 (enExample)
JP2017504578A5 (enExample)